tweetindex
EN

Bio Stocks™

@BioStocks · Toronto · joined 10 Feb 2010

Investor/trader focused primarily in the biopharma sector. Tweets are not investment advice and are not recommendations of any kind.

72 142Followers
92Following
61 532Posts total
57.4KViews on collected posts

Latest posts

$COYA Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS. Based on current screening and enrollment rates, topline data are anticipated in early Q2 4.3K views · 5 likes · 0 reposts · 2 replies Open on X →
$COGT FDA Accepts NDA for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) FDA communicated that at this time, there is no plan to hold an AdComm, nor have they identified any potential review issues. PDUFA 06/29/27 5.2K views · 24 likes · 6 reposts · 2 replies Open on X →
$OCUL plans to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence. NDA submission for wet AMD remains on track for Q4 6.4K views · 15 likes · 5 reposts · 2 replies Open on X →
$LLY to present new data on Foundayo, retatrutide, and eloraTZP at EASD26 Lilly will unveil Phase 2 data for eloraTZP, our latest triple-acting medicine combining the selective amylin receptor agonist eloralintide and GIP/GLP-1 receptor agonist tirzepatide 4.2K views · 7 likes · 0 reposts · 1 replies Open on X →
@BioStocks One Nordic biotech that may fit that theme: $SANION. Jazz + Acadia have already done deals on assets from its ion-channel platform; BI/AstronauTx also have programs. SAN2668 (DEE) + SAN2465 (TRD) near Phase 1, plus Phase 3 obesity optionality. Down ~60% despite pipelin 3 views · 0 likes · 0 reposts · 0 replies Open on X →
@BioStocks Why's it falling so bad today? 24 views · 0 likes · 0 reposts · 0 replies Open on X →
@BioStocks O really be like me okvdo this get paid I made ai ok I need help hears a stock tip pay me ten percent to tomorrow Title: TerraPolyGraphene (TPG) - Graphene-Silica Nanocomposite Additive Inventor: Jessie James Stalder Field: Nanomaterials, drilling fluids, thermal manag
34 views · 0 likes · 0 reposts · 0 replies Open on X →
Big Pharma M&A set for mega year as patent expiries drive deal urgency. $XBI $IBB If the current pace holds, 2026 biopharma M&A could top $250 billion, making it the #2 year on record after 2019’s $328 billion. #biotech https://t.co/Lcjadh7voY 37.3K views · 54 likes · 11 reposts · 4 replies Open on X →

Against accounts of the same size

6 posts from the last 90 days, next to the 10K–100K follower range. shown widely, but few of those viewers react.

Median views4 260this account935median for 10K–100K
Reach, %5.91%this account3.43%median for 10K–100K
Engagement, %0.18%this account1.55%median for 10K–100K
MetricThis accountMedian for 10K–100KRatio
Median views per post4 2609354.56×
Reach (views ÷ followers)5.91%3.43%1.72×
Engagement rate0.18%1.55%0.11×

Others in this range →   Compare with another account →   How these benchmarks are built →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

37.3K3 May
347 Jun
2427 Jul
37 Sep
4.2K15 Sep
6.4K
5.2K
4.3K

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.20%3 May
0.00%7 Jun
0.00%27 Jul
0.00%7 Sep
0.19%15 Sep
0.34%
0.62%
0.16%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.55%.

What the audience does

Likes65.6%105 in total
Reposts13.8%22 in total
Replies6.9%11 in total
Quotes3.8%6 in total
Bookmarks10.0%16 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Similar accounts